Page 1 | Search Results | The Journal of Immunology | American Association of Immunologists

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Subunit vaccine candidate with adjuvant confers protection against clinical Mycobacterium avium in wild type and immunocompromised mouse models

Sasha E Larsen, Valerie A Reese, TIffany Pecor, Guy Brewer, Bryan Berube, Samuel Njikan, Tanya Parish, Marcela Henao-Tamayo, Susan L Baldwin, Rhea N. Coler

J Immunol (2019) 202 (1_Supplement): 139.5.

https://doi.org/10.4049/jimmunol.202.Supp.139.5

Published: 01 May 2019

View article titled, Subunit vaccine candidate with adjuvant confers protection against clinical Mycobacterium avium in wild type and immunocompromised mouse models

Add to Citation Manager

Journal Articles

Use of GLA-nanoalum as an effective adjuvant for a therapeutic ID93 TB vaccine

Susan L. Baldwin, Sasha E. Larsen, Valerie A. Reese, Tiffany Pecor, Brian Granger, Amit Khandhar, Christopher B. Fox, Steven G. Reed, Rhea N. Coler

J Immunol (2018) 200 (1_Supplement): 180.21.

https://doi.org/10.4049/jimmunol.200.Supp.180.21

Published: 01 May 2018

View article titled, Use of GLA-nanoalum as an effective adjuvant for a therapeutic ID93 TB vaccine

Add to Citation Manager

Journal Articles

The TLR4 agonist vaccine adjuvant, GLA-SE, requires canonical and atypical mechanisms of action for T_H1 induction

Natasha Dubois Cauwelaert, Anthony L Desbien, Thomas E Hudson, Samuel O Pine, Steven G Reed, Rhea N. Coler, Mark T Orr

J Immunol (2016) 196 (1_Supplement): 75.7.

https://doi.org/10.4049/jimmunol.196.Supp.75.7

Published: 01 May 2016

View article titled, The TLR4 agonist vaccine adjuvant, GLA-SE, requires canonical and atypical mechanisms of action for TH1 induction

Add to Citation Manager

Journal Articles

Increased protection and decreased lung immunopathology induced by the ID93/GLA-SE vaccine candidate following infection with Mycobacterium tuberculosis HN878.

Susan L Baldwin, Valerie A. Reese, Po-wei D. Huang, Elyse A. Beebe, Brendan K. Podell, Steven G. Reed, Rhea N. Coler

J Immunol (2016) 196 (1_Supplement): 76.20.

https://doi.org/10.4049/jimmunol.196.Supp.76.20

Published: 01 May 2016

View article titled, Increased protection and decreased lung immunopathology induced by the ID93/GLA-SE vaccine candidate following infection with Mycobacterium tuberculosis HN878.

Add to Citation Manager

Journal Articles

Vaccination Produces CD4 T Cells with a Novel CD154–CD40-Dependent Cytolytic Mechanism

Rhea N. Coler, Thomas Hudson, Sean Hughes, Po-wei D. Huang, Elyse A. Beebe, Mark T. Orr

J Immunol (2015) 195 (7): 3190–3197.

https://doi.org/10.4049/jimmunol.1501118

Published: 01 October 2015

View article titled, Vaccination Produces CD4 T Cells with a Novel CD154–CD40-Dependent Cytolytic Mechanism

Add to Citation Manager

Journal Articles

Immune Subdominant Antigens as Vaccine Candidates against Mycobacterium tuberculosis

Mark T. Orr, Gregory C. Ireton, Elyse A. Beebe, Po-Wei D. Huang, Valerie A. Reese, David Argilla, Rhea N. Coler, Steven G. Reed

J Immunol (2014) 193 (6): 2911–2918.

https://doi.org/10.4049/jimmunol.1401103

Published: 15 September 2014

View article titled, Immune Subdominant Antigens as Vaccine Candidates against Mycobacterium tuberculosis

Add to Citation Manager

Includes: Supplementary data

Journal Articles

Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8⁺ T Cells

Susan L. Baldwin, Lance K. Ching, Samuel O. Pine, Magdalini Moutaftsi, Elyse Lucas, Aarthy Vallur, Mark T. Orr, Sylvie Bertholet, Steven G. Reed, Rhea N. Coler

J Immunol (2013) 191 (5): 2514–2525.

https://doi.org/10.4049/jimmunol.1301161

Published: 01 September 2013

View article titled, Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8+ T Cells

Add to Citation Manager

Includes: Supplementary data

Journal Articles

The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine

Susan L. Baldwin, Sylvie Bertholet, Valerie A. Reese, Lance K. Ching, Steven G. Reed, Rhea N. Coler

J Immunol (2012) 188 (5): 2189–2197.

https://doi.org/10.4049/jimmunol.1102696

Published: 01 March 2012

View article titled, The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine

Add to Citation Manager

Includes: Supplementary data

Journal Articles

Enhanced T helper 1 (Th1) responses with Fluzone® adjuvanted with a synthetic TLR4 agonist in an emulsion (45.15)

Susan L. Baldwin, Narek Shaverdian, Yasuyuki Goto, Malcolm S. Duthie, Tara Evers, Farah Mompoint, Tom S. Vedvick, Sylvie Bertholet, Rhea N. Coler, Steven G. Reed

J Immunol (2009) 182 (1_Supplement): 45.15.

https://doi.org/10.4049/jimmunol.182.Supp.45.15

Published: 01 April 2009

View article titled, Enhanced T helper 1 (Th1) responses with Fluzone® adjuvanted with a synthetic TLR4 agonist in an emulsion (45.15)

Add to Citation Manager

Journal Articles

Cross-protective humoral and cellular immune responses to A/H3N2 drifted influenza viruses following immunization with Fluzone® with a synthetic TLR4 agonist formulation (45.11)

Narek Shaverdian, Susan L. Baldwin, Steven J. Reed, Vanitha Raman, Yasu Goto, Farah Mompoint, Thomas S. Vedvick, Christopher H. Clegg, Rhea N. Coler, Steven G. Reed

J Immunol (2009) 182 (1_Supplement): 45.11.

https://doi.org/10.4049/jimmunol.182.Supp.45.11

Published: 01 April 2009

View article titled, Cross-protective humoral and cellular immune responses to A/H3N2 drifted influenza viruses following immunization with Fluzone® with a synthetic TLR4 agonist formulation (45.11)

Add to Citation Manager

Journal Articles

The role of IL-17 in the protective immune response to Mycobacterium tuberculosis (44.18)

Hillarie Plessner Windish, John Zheng, Sylvie Bertholet, Susan L Baldwin, Gregory C Ireton, Tom Vedvick, Steven G Reed, Rhea N Coler

J Immunol (2009) 182 (1_Supplement): 44.18.

https://doi.org/10.4049/jimmunol.182.Supp.44.18

Published: 01 April 2009

View article titled, The role of IL-17 in the protective immune response to Mycobacterium tuberculosis (44.18)

Add to Citation Manager

Journal Articles

Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis

Sylvie Bertholet, Gregory C. Ireton, Maria Kahn, Jeffrey Guderian, Raodoh Mohamath, Nicole Stride, Elsa M. Laughlin, Susan L. Baldwin, Thomas S. Vedvick, Rhea N. Coler, Steven G. Reed

J Immunol (2008) 181 (11): 7948–7957.

https://doi.org/10.4049/jimmunol.181.11.7948

Published: 01 December 2008

View article titled, Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis

Add to Citation Manager

Journal Articles

Vaccination with the T Cell Antigen Mtb 8.4 Protects Against Challenge with Mycobacterium tuberculosis

Rhea N. Coler, Antonio Campos-Neto, Pamela Ovendale, Fiona H. Day, Steven P. Fling, Liqing Zhu, Natalya Serbina, JoAnne L. Flynn, Steven G. Reed, Mark R. Alderson

J Immunol (2001) 166 (10): 6227–6235.

https://doi.org/10.4049/jimmunol.166.10.6227

Published: 15 May 2001

View article titled, Vaccination with the T Cell Antigen Mtb 8.4 Protects Against Challenge with Mycobacterium tuberculosis

Add to Citation Manager

Journal Articles

Molecular Cloning and Immunologic Reactivity of a Novel Low Molecular Mass Antigen of Mycobacterium tuberculosis

Rhea N. Coler, Yasir A. W. Skeiky, Thomas Vedvick, Teresa Bement, Pamela Ovendale, Antonio Campos-Neto, Mark R. Alderson, Steven G. Reed

J Immunol (1998) 161 (5): 2356–2364.

https://doi.org/10.4049/jimmunol.161.5.2356

Published: 01 September 1998

View article titled, Molecular Cloning and Immunologic Reactivity of a Novel Low Molecular Mass Antigen of Mycobacterium tuberculosis

Add to Citation Manager

NARROW

Subunit vaccine candidate with adjuvant confers protection against clinical Mycobacterium avium in wild type and immunocompromised mouse models

Use of GLA-nanoalum as an effective adjuvant for a therapeutic ID93 TB vaccine

The TLR4 agonist vaccine adjuvant, GLA-SE, requires canonical and atypical mechanisms of action for T_H1 induction

Increased protection and decreased lung immunopathology induced by the ID93/GLA-SE vaccine candidate following infection with Mycobacterium tuberculosis HN878.

Vaccination Produces CD4 T Cells with a Novel CD154–CD40-Dependent Cytolytic Mechanism

Immune Subdominant Antigens as Vaccine Candidates against Mycobacterium tuberculosis

Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8⁺ T Cells

The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine

Enhanced T helper 1 (Th1) responses with Fluzone® adjuvanted with a synthetic TLR4 agonist in an emulsion (45.15)

Cross-protective humoral and cellular immune responses to A/H3N2 drifted influenza viruses following immunization with Fluzone® with a synthetic TLR4 agonist formulation (45.11)

The role of IL-17 in the protective immune response to Mycobacterium tuberculosis (44.18)

Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis

Vaccination with the T Cell Antigen Mtb 8.4 Protects Against Challenge with Mycobacterium tuberculosis

Molecular Cloning and Immunologic Reactivity of a Novel Low Molecular Mass Antigen of Mycobacterium tuberculosis

Email alerts

Publications

Submit a Manuscript

General Information

Journal Services

Email alerts

Publications

Submit a Manuscript

General Information

Journal Services

This Feature Is Available To Subscribers Only